Education Hub

Pathology reports can be confusing. This article breaks down the key sections of a pathology report for squamous cell carcinoma, explaining common diagnoses, risk factors, and what medical terms really mean, so you can better understand your results.

A patient-centered guide to active surveillance, exploring the emotional challenges of living with ongoing monitoring and offering practical tools to manage anxiety before, during, and after dermatology appointments.

Comparison of Mohs vs. wide-local excision for adnexal carcinomas.

Jobs with UV or chemical exposure raise skin cancer risk; prevention steps included.

Explains SRT treatment for nonmelanoma skin cancers, side effects, and comparisons.

Guide to freezing precancerous and cancerous lesions, recovery, and follow-up needs.

Instructions for cleaning, dressing, and monitoring wounds after skin cancer surgery.

How gut health and probiotics impact inflammation and skin conditions, including cancers.

Explains electrical current–based skin cancer treatments, risks, and healing process.

Criteria doctors use to determine when Mohs surgery is the best treatment choice.

Role of peer groups and family guidance in recovery after skin cancer.

Rare skin cancer; signs, biopsy, treatments, and recurrence risk.

Signs, causes, and practical ways to prevent burnout during ongoing NMSC care.

Fast-growing skin cancer; risks, warning signs, staging, and core treatments.

When to use radiation, common side effects, and tips for skin care during

How biopsies and dermoscopy guide accurate skin cancer diagnosis.

How NMSC can spread, symptoms to watch for, and what staging means for treatment.

Snapshot of imiquimod, 5-FU, diclofenac, PDT, and when field therapy makes sense.

Quick facts to counter tanning, SPF, and “not at risk” misconceptions.

Overview of imiquimod, 5-FU, PDT, and when topical care is appropriate.

Who’s on your dermatology care team and how each specialist supports you.

SPF 30+, UPF clothing, shade, and smart habits to cut lifetime UV damage.

Easy daily checklist for sunscreen, clothing, shade, and reapplication.

Longer-term healing, scar maturity, and red flags to report.

What to expect in early healing and how to care for your wound.

Options to improve scars: silicone, massage, sun protection, and procedures.

Why it’s done, how it works, and what results can mean.

Where evidence stands and when non-surgical options are discussed.

UV-repair disorder; strict sun protection and multidisciplinary care.

Build support, manage symptoms, and protect mental well-being.

Mohs vs. wide-local excision outcomes in treating Extramammary Paget’s Disease.

Tumor-direct injections (5-FU, MTX, interferons, PDT): uses and follow-up.

When used, common side effects, and skin care during/after treatment.

SPF 30+, UPF clothing, shade; routine checks lower long-term cancer risk.

Virus-linked, aggressive; treated with surgery, RT, and immunotherapy.

NCCN exam intervals after BCC/SCC; higher-risk features need closer care.

Light-based removal for select lesions; quick recovery, not for invasive disease.

Short-course combo clears field damage; typical mild, temporary irritation.

Vismodegib/sonidegib for advanced BCC; benefits and common side effects.

Cutaneous HPV may contribute in immunosuppressed; vaccines under study.

Absorbable vs non-absorbable, mono vs multi, and size choices for optimal healing.

Drug + light targets superficial cancers; post-care light avoidance.

Imiquimod, 5-FU, TCA, retinoids: limited evidence and symptom-relief roles.

How signs differ, self-checks, and sun safety for every complexion.

Local injections; approved in melanoma, emerging data in NMSC.

Superficial/medium peels reduce AKs; best for precancers, not invasive SCC.

Lowers bleeding risk intra-/post-op; useful even on anticoagulants.

PTCH1-related; multiple BCCs, multidisciplinary monitoring, sun avoidance.

MMS offers superior local control; guidelines favor MMS/slow-Mohs.

Community and school interventions that improve UV-safe behaviors.

Brief reference on Surgical Management of MCC.

Sweat/sebaceous/hair tumors; diagnosis by biopsy; excision or Mohs.

Risks, common sites, and lesion- vs field-directed treatments plus prevention.

BCC/SCC risks (genetics, immunosuppression, UV); surgery first-line; prevention key.

Anxiety/depression common; communication and support improve outcomes.

500 mg BID lowers new NMSC in high-risk adults; use with core sun protection.

When leaving wounds open after Mohs helps; pros, cons, and care needs.

Who gets NMSC and why; access and equity shape outcomes.

Symptoms, biopsy diagnosis, surgery focus; recurrences need follow-up.

Signs, risk factors, biopsy, and treatment options from surgery to RT.

Rare, sun-linked tumor; excision/Mohs curative; monitor for recurrence.

Size/spread vs risk-factor staging; what stages mean for treatment planning.

Atypical sites/appearance; prompt biopsy and strong sun protection advised.

Summary of immunotherapy approaches and agents relevant to MCC.

SPF 30+, UPF clothing, shade, hydration, and kid-friendly checklists.

Eyelid-predominant, aggressive; biopsy, Mohs/excision, and lifelong follow-up.

Explains how having more than one cancer affects care.